Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (n = 3424) - Harbeck, N; Kates, RE; Look, MP (Cancer Res, 2002)
et al.